Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers
This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy volunteers with OATP1B1 *1b/*1b (n = 10), *1b/*15 (n = 7), or *15/*15 (n = 2) received oral administration of a cocktail of statins (atorvas...
Saved in:
Published in | Drug metabolism and pharmacokinetics Vol. 34; no. 1; pp. 78 - 86 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
England
Elsevier Ltd
01.02.2019
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy volunteers with OATP1B1 *1b/*1b (n = 10), *1b/*15 (n = 7), or *15/*15 (n = 2) received oral administration of a cocktail of statins (atorvastatin, pitavastatin, rosuvastatin, and fluvastatin). Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. OATP1B1 *15/*15 also showed higher mean plasma concentrations of OATP1B1 endogenous substrates compared with the other OATP1B1 genotypes, such as coproporphyrin I, glycochenodeoxycholate sulfate (GCDCA-S), lithocholate sulfate (LCA-S), glycolithocholate sulfate (GLCA-S) and taurolithocholate sulfate (TLCA-S), but not total or direct bilirubin, chenodeoxycholate-24-glucuronide, or ω-dicarboxylic long-chain fatty acids. Area under the plasma concentration-time curves of plasma coproporphyrin I and GLCA-S discriminated OATP1B1 genotype *15/*15 from the other genotypes. In combination with previously published clinical studies, these results support the notion that coproporphyrin I, and GLCA-S and GCDCA-S could be a surrogate probe for assessing human in vivo OATP1B1 activities.
[Display omitted] |
---|---|
AbstractList | This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy volunteers with OATP1B1 *1b/*1b (n = 10), *1b/*15 (n = 7), or *15/*15 (n = 2) received oral administration of a cocktail of statins (atorvastatin, pitavastatin, rosuvastatin, and fluvastatin). Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. OATP1B1 *15/*15 also showed higher mean plasma concentrations of OATP1B1 endogenous substrates compared with the other OATP1B1 genotypes, such as coproporphyrin I, glycochenodeoxycholate sulfate (GCDCA-S), lithocholate sulfate (LCA-S), glycolithocholate sulfate (GLCA-S) and taurolithocholate sulfate (TLCA-S), but not total or direct bilirubin, chenodeoxycholate-24-glucuronide, or ω-dicarboxylic long-chain fatty acids. Area under the plasma concentration-time curves of plasma coproporphyrin I and GLCA-S discriminated OATP1B1 genotype *15/*15 from the other genotypes. In combination with previously published clinical studies, these results support the notion that coproporphyrin I, and GLCA-S and GCDCA-S could be a surrogate probe for assessing human in vivo OATP1B1 activities. This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy volunteers with OATP1B1 *1b/*1b (n = 10), *1b/*15 (n = 7), or *15/*15 (n = 2) received oral administration of a cocktail of statins (atorvastatin, pitavastatin, rosuvastatin, and fluvastatin). Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. OATP1B1 *15/*15 also showed higher mean plasma concentrations of OATP1B1 endogenous substrates compared with the other OATP1B1 genotypes, such as coproporphyrin I, glycochenodeoxycholate sulfate (GCDCA-S), lithocholate sulfate (LCA-S), glycolithocholate sulfate (GLCA-S) and taurolithocholate sulfate (TLCA-S), but not total or direct bilirubin, chenodeoxycholate-24-glucuronide, or ω-dicarboxylic long-chain fatty acids. Area under the plasma concentration-time curves of plasma coproporphyrin I and GLCA-S discriminated OATP1B1 genotype *15/*15 from the other genotypes. In combination with previously published clinical studies, these results support the notion that coproporphyrin I, and GLCA-S and GCDCA-S could be a surrogate probe for assessing human in vivo OATP1B1 activities. [Display omitted] This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy volunteers with OATP1B1 *1b/*1b (n = 10), *1b/*15 (n = 7), or *15/*15 (n = 2) received oral administration of a cocktail of statins (atorvastatin, pitavastatin, rosuvastatin, and fluvastatin). Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. OATP1B1 *15/*15 also showed higher mean plasma concentrations of OATP1B1 endogenous substrates compared with the other OATP1B1 genotypes, such as coproporphyrin I, glycochenodeoxycholate sulfate (GCDCA-S), lithocholate sulfate (LCA-S), glycolithocholate sulfate (GLCA-S) and taurolithocholate sulfate (TLCA-S), but not total or direct bilirubin, chenodeoxycholate-24-glucuronide, or ω-dicarboxylic long-chain fatty acids. Area under the plasma concentration-time curves of plasma coproporphyrin I and GLCA-S discriminated OATP1B1 genotype *15/*15 from the other genotypes. In combination with previously published clinical studies, these results support the notion that coproporphyrin I, and GLCA-S and GCDCA-S could be a surrogate probe for assessing human in vivo OATP1B1 activities.This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy volunteers with OATP1B1 *1b/*1b (n = 10), *1b/*15 (n = 7), or *15/*15 (n = 2) received oral administration of a cocktail of statins (atorvastatin, pitavastatin, rosuvastatin, and fluvastatin). Mean area under the plasma concentration of atorvastatin, pitavastatin, and rosuvastatin in OATP1B1 *15/*15 were 2.2, 1.7 and 1.58-times greater than the corresponding values in OATP1B1 *1b/*1b, respectively, whereas that of fluvastatin was identical to those in other OATP1B1 genotypes. OATP1B1 *15/*15 also showed higher mean plasma concentrations of OATP1B1 endogenous substrates compared with the other OATP1B1 genotypes, such as coproporphyrin I, glycochenodeoxycholate sulfate (GCDCA-S), lithocholate sulfate (LCA-S), glycolithocholate sulfate (GLCA-S) and taurolithocholate sulfate (TLCA-S), but not total or direct bilirubin, chenodeoxycholate-24-glucuronide, or ω-dicarboxylic long-chain fatty acids. Area under the plasma concentration-time curves of plasma coproporphyrin I and GLCA-S discriminated OATP1B1 genotype *15/*15 from the other genotypes. In combination with previously published clinical studies, these results support the notion that coproporphyrin I, and GLCA-S and GCDCA-S could be a surrogate probe for assessing human in vivo OATP1B1 activities. |
Author | Hirota, Takeshi Sugiyama, Yuichi Mori, Daiki Yoshikado, Takashi Maeda, Kazuya Kashihara, Yushi Ieiri, Ichiro Irie, Shin Matsuki, Shunji Kimura, Miyuki Kusuhara, Hiroyuki |
Author_xml | – sequence: 1 givenname: Daiki surname: Mori fullname: Mori, Daiki organization: Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan – sequence: 2 givenname: Yushi surname: Kashihara fullname: Kashihara, Yushi organization: Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan – sequence: 3 givenname: Takashi surname: Yoshikado fullname: Yoshikado, Takashi organization: Sugiyama Lab, RIKEN Innovation Center, RIKEN, Yokohama, Japan – sequence: 4 givenname: Miyuki surname: Kimura fullname: Kimura, Miyuki organization: Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, 813-0017, Japan – sequence: 5 givenname: Takeshi surname: Hirota fullname: Hirota, Takeshi organization: Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan – sequence: 6 givenname: Shunji surname: Matsuki fullname: Matsuki, Shunji organization: Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, 813-0017, Japan – sequence: 7 givenname: Kazuya surname: Maeda fullname: Maeda, Kazuya organization: Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan – sequence: 8 givenname: Shin surname: Irie fullname: Irie, Shin organization: Fukuoka Mirai Hospital Clinical Research Center, Fukuoka, 813-0017, Japan – sequence: 9 givenname: Ichiro surname: Ieiri fullname: Ieiri, Ichiro organization: Department of Clinical Pharmacokinetics, Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, 812-8582, Japan – sequence: 10 givenname: Yuichi surname: Sugiyama fullname: Sugiyama, Yuichi organization: Sugiyama Lab, RIKEN Innovation Center, RIKEN, Yokohama, Japan – sequence: 11 givenname: Hiroyuki surname: Kusuhara fullname: Kusuhara, Hiroyuki email: kusuhara@mol.f.u-tokyo.ac.jp organization: Laboratory of Molecular Pharmacokinetics, Graduate School of Pharmaceutical Sciences, The University of Tokyo, Tokyo, Japan |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30528195$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kU1v1DAQhi1URNuFP8AB-ciBBE_sfElcSlUoUqVyKGfLsSddL4kdbKfS_gd-NMluy6GHnmYOz_NKM-85OXHeISHvgeXAoPq8y804_c4LBk3O2pwx_oqcQdOwjLUFO1l2LupM8Ko-Jecx7haAl6J4Q045K4sG2vKM_L3qe9SJ-p7eXtz9hK9A79H5tJ8wUu_oNKg4Kqq90-hSUMl6F1canfErOcf_Ypy7uCKLqZyhJsz38dNhTVu0gaoYvbaHCGod3aIa0nZPH_wwu4QY4lvyuldDxHePc0N-fbu6u7zObm6__7i8uMk0b1jKSmhAdLytQTGusVNClELVXS1Ux3vFmalq4GBqzVjXaxAGmRbQ67IU0DLgG_LxmDsF_2fGmORoo8ZhUA6Xg2QBZQlV1dTVgn54ROduRCOnYEcV9vLpgwvQHAEdfIwBe6ltOty4vMIOEphcy5I7uZYl17Ika-XaxYYUz9Sn9BelL0cJlwc9WAwyaotLO8aGpUhpvH1J_wcu8q5l |
CitedBy_id | crossref_primary_10_1016_j_ejps_2020_105264 crossref_primary_10_31146_1682_8658_ecg_206_10_70_76 crossref_primary_10_1002_cpt_2713 crossref_primary_10_1007_s43440_021_00319_y crossref_primary_10_1111_bcp_15679 crossref_primary_10_1124_dmd_121_000521 crossref_primary_10_1080_17425255_2019_1681399 crossref_primary_10_3389_fphar_2021_802539 crossref_primary_10_3390_molecules26185500 crossref_primary_10_1016_j_xphs_2023_09_016 crossref_primary_10_1038_s41598_020_70140_9 crossref_primary_10_1124_dmd_119_089474 crossref_primary_10_1002_jcph_2119 crossref_primary_10_1124_pharmrev_121_000449 crossref_primary_10_1111_cts_13272 crossref_primary_10_1002_cpt_1998 crossref_primary_10_1002_psp4_70008 crossref_primary_10_1016_j_dmpk_2019_12_004 crossref_primary_10_1007_s12272_023_01476_9 crossref_primary_10_1002_psp4_12582 crossref_primary_10_1111_cts_12625 crossref_primary_10_1016_j_xphs_2021_02_011 crossref_primary_10_1002_cpt_2053 crossref_primary_10_1007_s00280_021_04314_1 crossref_primary_10_1002_cpt_2375 crossref_primary_10_3999_jscpt_51_205 crossref_primary_10_1016_j_jphs_2021_10_010 crossref_primary_10_1021_acsptsci_3c00116 crossref_primary_10_1124_dmd_123_001074 crossref_primary_10_3390_biom15030428 crossref_primary_10_1016_j_yamp_2022_05_003 crossref_primary_10_1016_j_xphs_2019_03_021 crossref_primary_10_1124_dmd_124_001708 crossref_primary_10_1021_acs_molpharmaceut_0c00903 crossref_primary_10_2217_pme_2022_0041 crossref_primary_10_1002_jcph_1817 crossref_primary_10_1016_j_apsb_2022_03_009 crossref_primary_10_1016_j_dmpk_2020_09_003 crossref_primary_10_3389_fphar_2021_713567 crossref_primary_10_1002_cpt_1695 crossref_primary_10_1124_dmd_123_001285 crossref_primary_10_1002_cpt_2905 crossref_primary_10_1002_cpt_2429 crossref_primary_10_1111_cts_13731 crossref_primary_10_1124_dmd_122_000972 crossref_primary_10_1111_bph_16205 crossref_primary_10_1111_cts_12888 crossref_primary_10_1111_cts_12889 crossref_primary_10_1080_00498254_2019_1629043 crossref_primary_10_1124_dmd_119_087924 crossref_primary_10_1016_j_dmd_2024_100028 crossref_primary_10_1007_s40262_021_01004_2 crossref_primary_10_1002_cpt_2672 |
Cites_doi | 10.1097/FPC.0b013e3282fb02a3 10.1002/cpt.749 10.1002/jcph.723 10.1124/dmd.116.070276 10.1124/pr.113.007518 10.1248/bpb.b14-00767 10.1016/j.xphs.2017.03.010 10.1016/j.clpt.2006.06.010 10.1124/pr.110.002857 10.1016/j.jchromb.2017.12.008 10.1124/dmd.117.075531 10.1146/annurev-pharmtox-010611-134529 10.1111/bcp.13207 10.1097/FPC.0b013e3283517012 10.1007/s11095-018-2416-3 10.1007/s10038-008-0324-9 10.3109/00498254.2015.1085111 10.1007/s40262-018-0648-3 10.4155/bio-2017-0181 10.1007/s11095-017-2168-5 10.1016/j.xphs.2017.04.007 10.1517/17425250902976854 10.1016/j.cca.2006.05.010 10.1124/jpet.116.232066 10.1124/jpet.116.234914 10.1111/j.1349-7006.2008.00765.x 10.1124/pr.116.013326 10.1124/dmd.116.074740 10.1002/cpt.983 10.1002/psp4.12315 10.1002/cpt.434 10.1124/dmd.115.063347 10.1124/dmd.115.067694 10.1007/s11095-017-2184-5 10.1177/0091270007312153 10.1124/dmd.117.075275 |
ContentType | Journal Article |
Copyright | 2018 The Japanese Society for the Study of Xenobiotics Copyright © 2018 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. |
Copyright_xml | – notice: 2018 The Japanese Society for the Study of Xenobiotics – notice: Copyright © 2018 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.dmpk.2018.09.003 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1880-0920 |
EndPage | 86 |
ExternalDocumentID | 30528195 10_1016_j_dmpk_2018_09_003 S1347436718300776 |
Genre | Clinical Trial Journal Article |
GroupedDBID | --- --M 0R~ 29G 2WC 4.4 457 53G 5GY 7-5 8P~ AACTN AAEDT AAEDW AAIAV AAIKJ AAKOC AALRI AAOAW AATCM AAXUO ABJNI ABMAC ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE AEBSH AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGUBO AIEXJ AIKHN AITUG AJBFU AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BAWUL BKOJK BKOMP BLXMC CS3 DIK DU5 E3Z EBS EFJIC EFLBG EJD F5P FDB FEDTE FIRID FYGXN GBLVA GX1 HH5 HVGLF HZ~ JMI JSF JSH KOM KQ8 M41 MOJWN M~E O9- OAUVE RJT RNS ROL RZJ SPCBC SSP SSZ T5K TKC TR2 ~G- AAQFI AATTM AAXKI AAYWO AAYXX ACVFH ADCNI AEIPS AEUPX AFJKZ AFPUW AGCQF AGRNS AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP BNPGV CITATION OVT SSH CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c380t-51814b3971a03ceba4454a7b74ab3fa30d67131d7c00bfc14de0c41fc55419013 |
IEDL.DBID | AIKHN |
ISSN | 1347-4367 1880-0920 |
IngestDate | Fri Jul 11 07:22:29 EDT 2025 Thu Apr 03 07:03:03 EDT 2025 Thu Apr 24 22:51:52 EDT 2025 Tue Jul 01 03:08:28 EDT 2025 Fri Feb 23 02:27:11 EST 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Keywords | GCDCA-S Endogenous substrate Biomarker CDCA-24G Coproporphyrin I Gender difference DDI OATP1B3 MRM Statin LC–MS/MS OATP1B1 AUC CV CP-I OCT2 MATE1 TLCA-S OATP1B1 genotype LCA-S GLCA-S |
Language | English |
License | Copyright © 2018 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c380t-51814b3971a03ceba4454a7b74ab3fa30d67131d7c00bfc14de0c41fc55419013 |
Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
PMID | 30528195 |
PQID | 2155166876 |
PQPubID | 23479 |
PageCount | 9 |
ParticipantIDs | proquest_miscellaneous_2155166876 pubmed_primary_30528195 crossref_citationtrail_10_1016_j_dmpk_2018_09_003 crossref_primary_10_1016_j_dmpk_2018_09_003 elsevier_sciencedirect_doi_10_1016_j_dmpk_2018_09_003 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | February 2019 2019-02-00 2019-Feb 20190201 |
PublicationDateYYYYMMDD | 2019-02-01 |
PublicationDate_xml | – month: 02 year: 2019 text: February 2019 |
PublicationDecade | 2010 |
PublicationPlace | England |
PublicationPlace_xml | – name: England |
PublicationTitle | Drug metabolism and pharmacokinetics |
PublicationTitleAlternate | Drug Metab Pharmacokinet |
PublicationYear | 2019 |
Publisher | Elsevier Ltd |
Publisher_xml | – name: Elsevier Ltd |
References | Barnett, Ogungbenro, Menochet, Shen, Lai, Humphreys (bib33) 2018; 104 Yee, Giacomini, Hsueh, Weitz, Liang, Goswami (bib15) 2016; 100 Kiyotani, Mushiroda, Kubo, Zembutsu, Sugiyama, Nakamura (bib36) 2008; 99 Yoshikado, Maeda, Furihata, Terashima, Nakayama, Ishigame (bib29) 2017; 34 Shen, Chen, Drexler, Mandlekar, Holenarsipur, Shields (bib17) 2017; 45 Lee, Ho (bib9) 2017; 83 Chu, Shih, Shaw, Hentze, Chan, Owens (bib11) 2015; 43 Chu, Chan, Evers (bib5) 2017; 106 Shen, Dai, Liu, Cheng, Chen, Freeden (bib12) 2016; 357 Kunze, Ediage, Dillen, Monshouwer, Snoeys (bib24) 2018 Apr 16 Zhang, Yu, He, Fan, Li, Liu (bib27) 2006; 373 Niemi, Pasanen, Neuvonen (bib20) 2011; 63 Njumbe Ediage, Dillen, Vroman, Diels, Kunze, Snoeys (bib31) 2018; 1073 Rodrigues, Taskar, Kusuhara, Sugiyama (bib7) 2018; 103 Lai, Mandlekar, Shen, Holenarsipur, Langish, Rajanna (bib16) 2016; 358 Takehara, Yoshikado, Ishigame, Mori, Furihata, Watanabe (bib18) 2018; 35 Niemi, Pasanen, Neuvonen (bib25) 2006; 80 Bednarczyk, Boiselle (bib19) 2016; 46 Suwannakul, Ieiri, Kimura, Kawabata, Kusuhara, Hirota (bib23) 2008; 53 Gilibili, Chatterjee, Bagul, Mosure, Murali, Mariappan (bib35) 2017; 45 Ieiri, Higuchi, Sugiyama (bib21) 2009; 5 Vaidyanathan, Yoshida, Arya, Zhang (bib4) 2016; 56 Muller, Sharma, Konig, Fromm (bib6) 2018; 70 Kato, Kusuhara, Kumagai, Ieiri, Mori, Ito (bib22) 2012; 22 Yoshida, Guo, Sane (bib34) 2018; 7 Huang, Strong, Zhang, Reynolds, Nallani, Temple (bib1) 2008; 48 Takehara, Terashima, Nakayama, Yoshikado, Yoshida, Furihata (bib14) 2017; 34 Kim, Yoshikado, Ieiri, Maeda, Kimura, Irie (bib30) 2016; 44 Chu, Bleasby, Chan, Nunes, Evers (bib8) 2016; 44 Deng, Song, Shin, Yeo, Cho, Shon (bib26) 2008; 18 DeGorter, Xia, Yang, Kim (bib2) 2012; 52 Maeda (bib10) 2015; 38 Ramanathan, King-Ahmad, Holliman, Rodrigues (bib32) 2017; 9 Konig, Muller, Fromm (bib3) 2013; 65 Thakare, Gao, Kosa, Bi, Varma, Cerny (bib13) 2017; 45 Kashihara, Ieiri, Yoshikado, Maeda, Fukae, Kimura (bib28) 2017; 106 Thakare (10.1016/j.dmpk.2018.09.003_bib13) 2017; 45 Shen (10.1016/j.dmpk.2018.09.003_bib12) 2016; 357 Kim (10.1016/j.dmpk.2018.09.003_bib30) 2016; 44 Shen (10.1016/j.dmpk.2018.09.003_bib17) 2017; 45 Kato (10.1016/j.dmpk.2018.09.003_bib22) 2012; 22 Deng (10.1016/j.dmpk.2018.09.003_bib26) 2008; 18 Kashihara (10.1016/j.dmpk.2018.09.003_bib28) 2017; 106 Niemi (10.1016/j.dmpk.2018.09.003_bib25) 2006; 80 Konig (10.1016/j.dmpk.2018.09.003_bib3) 2013; 65 Ieiri (10.1016/j.dmpk.2018.09.003_bib21) 2009; 5 Muller (10.1016/j.dmpk.2018.09.003_bib6) 2018; 70 Kiyotani (10.1016/j.dmpk.2018.09.003_bib36) 2008; 99 Yoshikado (10.1016/j.dmpk.2018.09.003_bib29) 2017; 34 Chu (10.1016/j.dmpk.2018.09.003_bib5) 2017; 106 Bednarczyk (10.1016/j.dmpk.2018.09.003_bib19) 2016; 46 Takehara (10.1016/j.dmpk.2018.09.003_bib18) 2018; 35 Njumbe Ediage (10.1016/j.dmpk.2018.09.003_bib31) 2018; 1073 Maeda (10.1016/j.dmpk.2018.09.003_bib10) 2015; 38 Ramanathan (10.1016/j.dmpk.2018.09.003_bib32) 2017; 9 Barnett (10.1016/j.dmpk.2018.09.003_bib33) 2018; 104 Lai (10.1016/j.dmpk.2018.09.003_bib16) 2016; 358 Lee (10.1016/j.dmpk.2018.09.003_bib9) 2017; 83 Yee (10.1016/j.dmpk.2018.09.003_bib15) 2016; 100 Yoshida (10.1016/j.dmpk.2018.09.003_bib34) 2018; 7 Huang (10.1016/j.dmpk.2018.09.003_bib1) 2008; 48 Zhang (10.1016/j.dmpk.2018.09.003_bib27) 2006; 373 Suwannakul (10.1016/j.dmpk.2018.09.003_bib23) 2008; 53 Chu (10.1016/j.dmpk.2018.09.003_bib11) 2015; 43 Kunze (10.1016/j.dmpk.2018.09.003_bib24) 2018 Vaidyanathan (10.1016/j.dmpk.2018.09.003_bib4) 2016; 56 DeGorter (10.1016/j.dmpk.2018.09.003_bib2) 2012; 52 Rodrigues (10.1016/j.dmpk.2018.09.003_bib7) 2018; 103 Takehara (10.1016/j.dmpk.2018.09.003_bib14) 2017; 34 Chu (10.1016/j.dmpk.2018.09.003_bib8) 2016; 44 Gilibili (10.1016/j.dmpk.2018.09.003_bib35) 2017; 45 Niemi (10.1016/j.dmpk.2018.09.003_bib20) 2011; 63 |
References_xml | – volume: 45 start-page: 721 year: 2017 end-page: 733 ident: bib13 article-title: Leveraging of rifampicin-dosed cynomolgus monkeys to identify bile acid 3-O-sulfate conjugates as potential novel biomarkers for organic anion-transporting polypeptides publication-title: Drug Metab Dispos – volume: 18 start-page: 424 year: 2008 end-page: 433 ident: bib26 article-title: The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15 publication-title: Pharmacogenet Genomics – volume: 44 start-page: 1498 year: 2016 end-page: 1509 ident: bib8 article-title: The complexities of interpreting reversible elevated serum creatinine levels in drug development: does a correlation with inhibition of renal transporters exist? publication-title: Drug Metab Dispos – volume: 52 start-page: 249 year: 2012 end-page: 273 ident: bib2 article-title: Drug transporters in drug efficacy and toxicity publication-title: Annu Rev Pharmacol Toxicol – volume: 56 start-page: S59 year: 2016 end-page: S72 ident: bib4 article-title: Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1 publication-title: J Clin Pharmacol – volume: 100 start-page: 524 year: 2016 end-page: 536 ident: bib15 article-title: Metabolomic and genome-wide association studies reveal potential endogenous biomarkers for OATP1B1 publication-title: Clin Pharmacol Ther – volume: 70 start-page: 246 year: 2018 end-page: 277 ident: bib6 article-title: Biomarkers for in vivo assessment of transporter function publication-title: Pharmacol Rev – volume: 45 start-page: 604 year: 2017 end-page: 611 ident: bib35 article-title: Coproporphyrin-I: a fluorescent, endogenous optimal probe substrate for ABCC2 (MRP2) suitable for vesicle-based MRP2 inhibition assay publication-title: Drug Metab Dispos – volume: 99 start-page: 967 year: 2008 end-page: 972 ident: bib36 article-title: Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia publication-title: Cancer Sci – volume: 63 start-page: 157 year: 2011 end-page: 181 ident: bib20 article-title: Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake publication-title: Pharmacol Rev – volume: 65 start-page: 944 year: 2013 end-page: 966 ident: bib3 article-title: Transporters and drug-drug interactions: important determinants of drug disposition and effects publication-title: Pharmacol Rev – volume: 22 start-page: 344 year: 2012 end-page: 354 ident: bib22 article-title: Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals publication-title: Pharmacogenet Genomics – volume: 358 start-page: 397 year: 2016 end-page: 404 ident: bib16 article-title: Coproporphyrins in plasma and urine can Be appropriate clinical biomarkers to recapitulate drug-drug interactions mediated by organic anion transporting polypeptide inhibition publication-title: J Pharmacol Exp Ther – volume: 106 start-page: 2688 year: 2017 end-page: 2694 ident: bib28 article-title: Small-dosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1 and ABCG2), and interaction (atorvastatin and grapefruit juice) profiles of 5 probes for OATP2B1 and BCRP publication-title: J Pharm Sci – volume: 357 start-page: 382 year: 2016 end-page: 393 ident: bib12 article-title: Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species publication-title: J Pharmacol Exp Ther – volume: 48 start-page: 662 year: 2008 end-page: 670 ident: bib1 article-title: New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process publication-title: J Clin Pharmacol – volume: 7 start-page: 517 year: 2018 end-page: 524 ident: bib34 article-title: Quantitative prediction of OATP-mediated drug-drug interactions with model-based analysis of endogenous biomarker kinetics publication-title: CPT Pharmacometrics Syst Pharmacol – volume: 9 start-page: 1787 year: 2017 end-page: 1806 ident: bib32 article-title: A highly selective and sensitive LC-MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers publication-title: Bioanalysis – volume: 104 start-page: 564 year: 2018 end-page: 574 ident: bib33 article-title: Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modeling and simulation publication-title: Clin Pharmacol Ther – year: 2018 Apr 16 ident: bib24 article-title: Clinical investigation of coproporphyrins as sensitive biomarkers to predict mild to strong OATP1B-mediated drug-drug interactions publication-title: Clin Pharmacokinet – volume: 45 start-page: 908 year: 2017 end-page: 919 ident: bib17 article-title: Comparative evaluation of plasma bile acids, dehydroepiandrosterone sulfate, hexadecanedioate, and tetradecanedioate with coproporphyrins I and III as markers of OATP inhibition in healthy subjects publication-title: Drug Metab Dispos – volume: 43 start-page: 851 year: 2015 end-page: 863 ident: bib11 article-title: Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans publication-title: Drug Metab Dispos – volume: 44 start-page: 1622 year: 2016 end-page: 1632 ident: bib30 article-title: Clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information publication-title: Drug Metab Dispos – volume: 106 start-page: 2357 year: 2017 end-page: 2367 ident: bib5 article-title: Identification of endogenous biomarkers to predict the propensity of drug candidates to cause hepatic or renal transporter-mediated drug-drug interactions publication-title: J Pharmaceut Sci – volume: 34 start-page: 1570 year: 2017 end-page: 1583 ident: bib29 article-title: A clinical cassette dosing study for evaluating the contribution of hepatic OATPs and CYP3A to drug-drug interactions publication-title: Pharm Res – volume: 373 start-page: 99 year: 2006 end-page: 103 ident: bib27 article-title: Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males publication-title: Clin Chim Acta – volume: 103 start-page: 434 year: 2018 end-page: 448 ident: bib7 article-title: Endogenous probes for drug transporters: balancing vision with reality publication-title: Clin Pharmacol Ther – volume: 5 start-page: 703 year: 2009 end-page: 729 ident: bib21 article-title: Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs publication-title: Expert Opin Drug Metab Toxicol – volume: 1073 start-page: 80 year: 2018 end-page: 89 ident: bib31 article-title: Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions publication-title: J Chromatogr B Analyt Technol Biomed Life Sci – volume: 38 start-page: 155 year: 2015 end-page: 168 ident: bib10 article-title: Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs publication-title: Biol Pharm Bull – volume: 35 start-page: 138 year: 2018 ident: bib18 article-title: Comparative study of the dose-dependence of OATP1B inhibition by rifampicin using probe drugs and endogenous substrates in healthy volunteers publication-title: Pharm Res – volume: 83 start-page: 1176 year: 2017 end-page: 1184 ident: bib9 article-title: Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1) publication-title: Br J Clin Pharmacol – volume: 80 start-page: 356 year: 2006 end-page: 366 ident: bib25 article-title: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin publication-title: Clin Pharmacol Ther – volume: 34 start-page: 1601 year: 2017 end-page: 1614 ident: bib14 article-title: Investigation of glycochenodeoxycholate sulfate and chenodeoxycholate glucuronide as surrogate endogenous probes for drug interaction studies of OATP1B1 and OATP1B3 in healthy Japanese volunteers publication-title: Pharm Res – volume: 53 start-page: 899 year: 2008 end-page: 904 ident: bib23 article-title: Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism publication-title: J Hum Genet – volume: 46 start-page: 457 year: 2016 end-page: 466 ident: bib19 article-title: Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III publication-title: Xenobiotica – volume: 18 start-page: 424 year: 2008 ident: 10.1016/j.dmpk.2018.09.003_bib26 article-title: The effect of SLCO1B1*15 on the disposition of pravastatin and pitavastatin is substrate dependent: the contribution of transporting activity changes by SLCO1B1*15 publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e3282fb02a3 – volume: 103 start-page: 434 year: 2018 ident: 10.1016/j.dmpk.2018.09.003_bib7 article-title: Endogenous probes for drug transporters: balancing vision with reality publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.749 – volume: 56 start-page: S59 issue: Suppl. 7 year: 2016 ident: 10.1016/j.dmpk.2018.09.003_bib4 article-title: Comparing various in vitro prediction criteria to assess the potential of a new molecular entity to inhibit organic anion transporting polypeptide 1B1 publication-title: J Clin Pharmacol doi: 10.1002/jcph.723 – volume: 44 start-page: 1622 year: 2016 ident: 10.1016/j.dmpk.2018.09.003_bib30 article-title: Clarification of the mechanism of clopidogrel-mediated drug-drug interaction in a clinical cassette small-dose study and its prediction based on in vitro information publication-title: Drug Metab Dispos doi: 10.1124/dmd.116.070276 – volume: 65 start-page: 944 year: 2013 ident: 10.1016/j.dmpk.2018.09.003_bib3 article-title: Transporters and drug-drug interactions: important determinants of drug disposition and effects publication-title: Pharmacol Rev doi: 10.1124/pr.113.007518 – volume: 38 start-page: 155 year: 2015 ident: 10.1016/j.dmpk.2018.09.003_bib10 article-title: Organic anion transporting polypeptide (OATP)1B1 and OATP1B3 as important regulators of the pharmacokinetics of substrate drugs publication-title: Biol Pharm Bull doi: 10.1248/bpb.b14-00767 – volume: 106 start-page: 2688 year: 2017 ident: 10.1016/j.dmpk.2018.09.003_bib28 article-title: Small-dosing clinical study: pharmacokinetic, pharmacogenomic (SLCO2B1 and ABCG2), and interaction (atorvastatin and grapefruit juice) profiles of 5 probes for OATP2B1 and BCRP publication-title: J Pharm Sci doi: 10.1016/j.xphs.2017.03.010 – volume: 80 start-page: 356 year: 2006 ident: 10.1016/j.dmpk.2018.09.003_bib25 article-title: SLCO1B1 polymorphism and sex affect the pharmacokinetics of pravastatin but not fluvastatin publication-title: Clin Pharmacol Ther doi: 10.1016/j.clpt.2006.06.010 – volume: 63 start-page: 157 year: 2011 ident: 10.1016/j.dmpk.2018.09.003_bib20 article-title: Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake publication-title: Pharmacol Rev doi: 10.1124/pr.110.002857 – volume: 1073 start-page: 80 year: 2018 ident: 10.1016/j.dmpk.2018.09.003_bib31 article-title: Development of an LC-MS method to quantify coproporphyrin I and III as endogenous biomarkers for drug transporter-mediated drug-drug interactions publication-title: J Chromatogr B Analyt Technol Biomed Life Sci doi: 10.1016/j.jchromb.2017.12.008 – volume: 45 start-page: 908 year: 2017 ident: 10.1016/j.dmpk.2018.09.003_bib17 article-title: Comparative evaluation of plasma bile acids, dehydroepiandrosterone sulfate, hexadecanedioate, and tetradecanedioate with coproporphyrins I and III as markers of OATP inhibition in healthy subjects publication-title: Drug Metab Dispos doi: 10.1124/dmd.117.075531 – volume: 52 start-page: 249 year: 2012 ident: 10.1016/j.dmpk.2018.09.003_bib2 article-title: Drug transporters in drug efficacy and toxicity publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev-pharmtox-010611-134529 – volume: 83 start-page: 1176 year: 2017 ident: 10.1016/j.dmpk.2018.09.003_bib9 article-title: Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1) publication-title: Br J Clin Pharmacol doi: 10.1111/bcp.13207 – volume: 22 start-page: 344 year: 2012 ident: 10.1016/j.dmpk.2018.09.003_bib22 article-title: Association of multidrug resistance-associated protein 2 single nucleotide polymorphism rs12762549 with the basal plasma levels of phase II metabolites of isoflavonoids in healthy Japanese individuals publication-title: Pharmacogenet Genomics doi: 10.1097/FPC.0b013e3283517012 – volume: 35 start-page: 138 issue: 7 year: 2018 ident: 10.1016/j.dmpk.2018.09.003_bib18 article-title: Comparative study of the dose-dependence of OATP1B inhibition by rifampicin using probe drugs and endogenous substrates in healthy volunteers publication-title: Pharm Res doi: 10.1007/s11095-018-2416-3 – volume: 53 start-page: 899 year: 2008 ident: 10.1016/j.dmpk.2018.09.003_bib23 article-title: Pharmacokinetic interaction between pravastatin and olmesartan in relation to SLCO1B1 polymorphism publication-title: J Hum Genet doi: 10.1007/s10038-008-0324-9 – volume: 46 start-page: 457 year: 2016 ident: 10.1016/j.dmpk.2018.09.003_bib19 article-title: Organic anion transporting polypeptide (OATP)-mediated transport of coproporphyrins I and III publication-title: Xenobiotica doi: 10.3109/00498254.2015.1085111 – year: 2018 ident: 10.1016/j.dmpk.2018.09.003_bib24 article-title: Clinical investigation of coproporphyrins as sensitive biomarkers to predict mild to strong OATP1B-mediated drug-drug interactions publication-title: Clin Pharmacokinet doi: 10.1007/s40262-018-0648-3 – volume: 9 start-page: 1787 year: 2017 ident: 10.1016/j.dmpk.2018.09.003_bib32 article-title: A highly selective and sensitive LC-MS/HRMS assay for quantifying coproporphyrins as organic anion-transporting peptide biomarkers publication-title: Bioanalysis doi: 10.4155/bio-2017-0181 – volume: 34 start-page: 1570 year: 2017 ident: 10.1016/j.dmpk.2018.09.003_bib29 article-title: A clinical cassette dosing study for evaluating the contribution of hepatic OATPs and CYP3A to drug-drug interactions publication-title: Pharm Res doi: 10.1007/s11095-017-2168-5 – volume: 106 start-page: 2357 year: 2017 ident: 10.1016/j.dmpk.2018.09.003_bib5 article-title: Identification of endogenous biomarkers to predict the propensity of drug candidates to cause hepatic or renal transporter-mediated drug-drug interactions publication-title: J Pharmaceut Sci doi: 10.1016/j.xphs.2017.04.007 – volume: 5 start-page: 703 year: 2009 ident: 10.1016/j.dmpk.2018.09.003_bib21 article-title: Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs publication-title: Expert Opin Drug Metab Toxicol doi: 10.1517/17425250902976854 – volume: 373 start-page: 99 year: 2006 ident: 10.1016/j.dmpk.2018.09.003_bib27 article-title: Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males publication-title: Clin Chim Acta doi: 10.1016/j.cca.2006.05.010 – volume: 357 start-page: 382 year: 2016 ident: 10.1016/j.dmpk.2018.09.003_bib12 article-title: Coproporphyrins I and III as functional markers of OATP1B activity: in vitro and in vivo evaluation in preclinical species publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.116.232066 – volume: 358 start-page: 397 year: 2016 ident: 10.1016/j.dmpk.2018.09.003_bib16 article-title: Coproporphyrins in plasma and urine can Be appropriate clinical biomarkers to recapitulate drug-drug interactions mediated by organic anion transporting polypeptide inhibition publication-title: J Pharmacol Exp Ther doi: 10.1124/jpet.116.234914 – volume: 99 start-page: 967 year: 2008 ident: 10.1016/j.dmpk.2018.09.003_bib36 article-title: Association of genetic polymorphisms in SLCO1B3 and ABCC2 with docetaxel-induced leukopenia publication-title: Cancer Sci doi: 10.1111/j.1349-7006.2008.00765.x – volume: 70 start-page: 246 year: 2018 ident: 10.1016/j.dmpk.2018.09.003_bib6 article-title: Biomarkers for in vivo assessment of transporter function publication-title: Pharmacol Rev doi: 10.1124/pr.116.013326 – volume: 45 start-page: 604 year: 2017 ident: 10.1016/j.dmpk.2018.09.003_bib35 article-title: Coproporphyrin-I: a fluorescent, endogenous optimal probe substrate for ABCC2 (MRP2) suitable for vesicle-based MRP2 inhibition assay publication-title: Drug Metab Dispos doi: 10.1124/dmd.116.074740 – volume: 104 start-page: 564 year: 2018 ident: 10.1016/j.dmpk.2018.09.003_bib33 article-title: Gaining mechanistic insight into coproporphyrin I as endogenous biomarker for OATP1B-mediated drug-drug interactions using population pharmacokinetic modeling and simulation publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.983 – volume: 7 start-page: 517 issue: 8 year: 2018 ident: 10.1016/j.dmpk.2018.09.003_bib34 article-title: Quantitative prediction of OATP-mediated drug-drug interactions with model-based analysis of endogenous biomarker kinetics publication-title: CPT Pharmacometrics Syst Pharmacol doi: 10.1002/psp4.12315 – volume: 100 start-page: 524 year: 2016 ident: 10.1016/j.dmpk.2018.09.003_bib15 article-title: Metabolomic and genome-wide association studies reveal potential endogenous biomarkers for OATP1B1 publication-title: Clin Pharmacol Ther doi: 10.1002/cpt.434 – volume: 43 start-page: 851 year: 2015 ident: 10.1016/j.dmpk.2018.09.003_bib11 article-title: Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.063347 – volume: 44 start-page: 1498 year: 2016 ident: 10.1016/j.dmpk.2018.09.003_bib8 article-title: The complexities of interpreting reversible elevated serum creatinine levels in drug development: does a correlation with inhibition of renal transporters exist? publication-title: Drug Metab Dispos doi: 10.1124/dmd.115.067694 – volume: 34 start-page: 1601 year: 2017 ident: 10.1016/j.dmpk.2018.09.003_bib14 article-title: Investigation of glycochenodeoxycholate sulfate and chenodeoxycholate glucuronide as surrogate endogenous probes for drug interaction studies of OATP1B1 and OATP1B3 in healthy Japanese volunteers publication-title: Pharm Res doi: 10.1007/s11095-017-2184-5 – volume: 48 start-page: 662 year: 2008 ident: 10.1016/j.dmpk.2018.09.003_bib1 article-title: New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process publication-title: J Clin Pharmacol doi: 10.1177/0091270007312153 – volume: 45 start-page: 721 year: 2017 ident: 10.1016/j.dmpk.2018.09.003_bib13 article-title: Leveraging of rifampicin-dosed cynomolgus monkeys to identify bile acid 3-O-sulfate conjugates as potential novel biomarkers for organic anion-transporting polypeptides publication-title: Drug Metab Dispos doi: 10.1124/dmd.117.075275 |
SSID | ssj0033542 |
Score | 2.417561 |
Snippet | This study aimed to elucidate the impact of OATP1B1 genotype (*1b/*1b, *1b/*15, and *15/*15) on plasma concentrations of endogenous OATP1B1 substrates. Healthy... |
SourceID | proquest pubmed crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 78 |
SubjectTerms | Adult Biomarker Coproporphyrin I Endogenous substrate Female Gender difference Genotype Healthy Volunteers Humans Hydroxymethylglutaryl-CoA Reductase Inhibitors - administration & dosage Hydroxymethylglutaryl-CoA Reductase Inhibitors - blood Liver-Specific Organic Anion Transporter 1 - blood Liver-Specific Organic Anion Transporter 1 - genetics Male OATP1B1 genotype Pharmaceutical Preparations - administration & dosage Pharmaceutical Preparations - blood Statin Substrate Specificity - physiology Young Adult |
Title | Effect of OATP1B1 genotypes on plasma concentrations of endogenous OATP1B1 substrates and drugs, and their association in healthy volunteers |
URI | https://dx.doi.org/10.1016/j.dmpk.2018.09.003 https://www.ncbi.nlm.nih.gov/pubmed/30528195 https://www.proquest.com/docview/2155166876 |
Volume | 34 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9swDBa69LLLsHav7AUNGHpZjciRbMfHrFiRLUAXbCnWm6CXi2yrEtTpIf9hP7qkJCcohvWwkx8QYUGkyc8W-ZGQ97rWnIuaZRU3OhOC8WyU8yJzSlvHK8CwMcv3rJyciy8XxcUeOelqYTCtMvn-6NODt053Bmk1B6vFYvAdiyAFL8G58kBK84DsDyG6sh7ZH3-eTs46h8x5EXro4PgMBVLtTEzzslerX5jhNQp0p13vrL_j07_wZ4hDp4_JowQg6TjO8YDsOX9IjmaRgXpzTOe7gqr2mB7R2Y6bevOE_IlsxXTZ0K_j-Sz_mFNkacUfsS1deroCMH2lqMFiRp8YdVsc7bxdRj7XrWALPidw27ZUeUvt9c0lPBFPw-4DVTvN04WnseJyQ9EfgjYBdj4l56ef5ieTLDVkyAwfsXVWABwQGtY4V4wbp5UQhVCVroTSvFGcWdAGz21lGNONyYV1zIi8MYBZEHjwZ6Tnl969INSqoRN1BfjNGeFGjbKKWfjYK412ZdU0fZJ3apAmsZVj04zfsktL-ylRdRJVJ1mNHKd98mErs4pcHfeOLjrtyjsWJyGY3Cv3rjMFCa8i7q8o72D55TDsOpYQX_rkebSR7TzArYYty5f_-dRX5CFc1TFf_DXpra9v3BuAQ2v9Npk7HqfffkxvAbUlCtk |
linkProvider | Elsevier |
linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfG9gAviPFZYMNIaC8sqjM7SfNYpk0dG6USnbQ3y1-ZCsytlu6h_wN_NHe20woh9sBblPhky3e5-yW--x0hH3StORc1yypudCYE49kg50XmlLaOV4BhY5bvuBxdis9XxdUWOe5qYTCtMvn-6NODt053-mk3-4vZrP8NiyAFL8G58kBK84DsIDsVmPnO8Ox8NO4cMudF6KGD4zMUSLUzMc3L3ix-YIbXINCddr2z_o5P_8KfIQ6dPiGPE4Ckw7jGXbLl_FNyMIkM1KtDOt0UVLWH9IBONtzUq2fkV2QrpvOGfh1OJ_mnnCJLK_6Ibenc0wWA6RtFDRYz-sSo2-Jo5-088rmuBVvwOYHbtqXKW2pv765hRrwMpw9UbTRPZ57GissVRX8I2gTY-Zxcnp5Mj0dZasiQGT5gy6wAOCA0IJhcMW6cVgI2XFW6EkrzRnFmQRs8t5VhTDcmF9YxI_LGAGZB4MFfkG0_9-4VoVYdOVFXgN-cEW7QKKuYhY-90mhXVk3TI3mnBmkSWzk2zfgpu7S07xJVJ1F1ktXIcdojH9cyi8jVce_ootOu_MPiJASTe-Xed6Yg4VXE8xXlHWy_PAqnjiXElx55GW1kvQ5wq-HI8vV_zvqOPBxNv1zIi7Px-RvyCJ7UMXf8Ldle3t65PYBGS72fTP83A5wMJQ |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Effect+of+OATP1B1+genotypes+on+plasma+concentrations+of+endogenous+OATP1B1+substrates+and+drugs%2C+and+their+association+in+healthy+volunteers&rft.jtitle=Drug+metabolism+and+pharmacokinetics&rft.au=Mori%2C+Daiki&rft.au=Kashihara%2C+Yushi&rft.au=Yoshikado%2C+Takashi&rft.au=Kimura%2C+Miyuki&rft.date=2019-02-01&rft.issn=1347-4367&rft.volume=34&rft.issue=1&rft.spage=78&rft.epage=86&rft_id=info:doi/10.1016%2Fj.dmpk.2018.09.003&rft.externalDBID=n%2Fa&rft.externalDocID=10_1016_j_dmpk_2018_09_003 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1347-4367&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1347-4367&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1347-4367&client=summon |